ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

ClinicalTrials.gov ID: NCT00104871

Public ClinicalTrials.gov record NCT00104871. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 12:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma

Study identification

NCT ID
NCT00104871
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
24 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2004
Primary completion
Apr 30, 2010
Completion
Mar 31, 2014
Last update posted
Dec 18, 2018

2004 – 2014

United States locations

U.S. sites
9
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
University of Colorado at Denver Health Sciences Center Aurora Colorado 80045
Lombardi Comprehensive Cancer Center at Georgetown University Washington D.C. District of Columbia 20057
Emory University Atlanta Georgia 30322
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114
Dana-Farber Harvard Cancer Center Boston Massachusetts 02115
Cleveland Clinic Foundation Cleveland Ohio 44195
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland Ohio 44195
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus Ohio 43210
M D Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00104871, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 18, 2018 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00104871 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →